Drug Trial Radar · NCT00578786
A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
Last checked: Nov 20, 2026Latest source record: Jan 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
383
Actual
Start
Feb 2004
Primary completion
Mar 2010
Study completion Mar 2010
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Dec 21, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AMB-320/321-E was designed to provide long-term, controlled monitoring of pulmonary arterial hypertension (PAH) patients treated with ambrisentan (AMB) in order to properly define the adverse event profile associated with this endothelin receptor antagonist (ERA), including the incidence and severity of elevated serum liver function tests (LFTs). In addition, this study continued the efficacy assessments of the previous studies, examined long-term AMB treatment success, and compared long-term survival of subjects treated with AMB to the NIH registry of patients with PAH.
Conditions
- Pulmonary Arterial Hypertension
Interventions
ambrisentanDrug
2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequently Reported (15% or More Overall) Adverse Events by SeverityTime frame: Baseline to Week 295
- Serum Aminotransferases Relative to the Upper Limit of the Normal Range (ULN)Time frame: Baseline to Week 295
Locations
22 sites in 4 countries. Site status is shown where the registry gives one.
Hospital Privado Centro Medico de Cordoba
Córdoba, Argentina
Sanatorio Otamendi
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Britanico-Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Instituto del Corazon Denton A. Cooley
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
UAI Hosp. Universitario
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
HIGA Hospital Interzonal General de Agudos Oscar Allende
Mar del Plata, Buenos Aires, Argentina
Clinica Independencia Munro
Munro, Buenos Aires, Argentina
Sanatorio Allende
Córdoba, Córdoba Province, Argentina
Hospital Italiano de Cordoba
Córdoba, Córdoba Province, Argentina
Instituto de Cardiologia J.F. Cabral
Corrientes, Corrientes Province, Argentina
Hospital Italiano de Rosario
Rosario, Sante Fe, Argentina
Hospital Madre Teresa
Belo Horizonte, Brazil
Hospital San Lucas de Pontificia Universidade Catolica
Porto Alegre, Brazil
Complexo Hospitalar Sanata Casa de Porto Alegre
Porto Alegre, Brazil
Universidade do Estado de Sao Paulo - UNIFESP
São Paulo, Brazil
Hospital das Clinicas da FMUSP
São Paulo, Brazil
Hospital Universitario Clementino Fraga Filho
Ilha Do Fundao, Rio de Janeiro, Brazil
Hospital San Juan de Dios
Santiago, Santiago de Chile, Chile
Hospital Clinico Universidad Catolica
Santiago, Santiago de Chile, Chile
Instituto Nacional del Torax
Santiago, Santiago de Chile, Chile
Instituto Nacional de Cardiologia Ignacio Chavez
Mexico City, Mexico City, Mexico
Unidad De Investigacion Clinica en Medicina
Monterrey, Nuevo Leon, Nuevo León, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.